Navigation Links
SeraCare Shareholders Approve Acquisition by Linden Capital Partners
Date:4/18/2012

MILFORD, Mass., April 18, 2012 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced that, at a special meeting of shareholders held today, its shareholders voted to adopt the merger agreement with Project Plasma Holdings Corporation and Project Plasma Merger Corp., affiliates of Linden Capital Partners. Linden Capital Partners is a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

(Logo:  http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )

Under the terms of the merger agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share. The transaction is expected to close on Friday, April 20, 2012 after the close of business, subject to the satisfaction of customary closing conditions. In addition, shareholders also voted to approve certain compensation arrangements for SeraCare's named executive officers in connection with the merger.

About Linden Capital Partners:

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's investment strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden has advised SeraCare that it currently manages $575 million in capital. For additional information, please visit www.lindenllc.com.

About SeraCare Life Sciences, Inc.:

SeraCare serves the g
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SeraCare Life Sciences Secures $20 Million Credit Facilities
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
5. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
6. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
7. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
8. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Mymetics Corporation Important Shareholders Information Conference Call
11. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... innovative Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und ... Royal Philips (NYSE: PHG, ... Europäischen Röntgenkongress 2015 (ECR) bekannt, der vom ... stattfindet. An den Ständen Nr. 102 and ...
(Date:3/3/2015)... 2015 Experts and industry insiders from ... event: the Alltech REBELation exploring innovation, inspiration and world-changing ... in its 31st year, Alltech’s annual international conference traditionally ... the opportunity to join the REBELation at an extra ... p.m. EST, at which point the standard early registration ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC Bulletin ... in the development of and commercialization of regenerative cell ... organs, announced today that it has received the final ... Bioscience Holdings, Inc. (OTC Bulletin Board: AMBS ... Amarantus made the final payments due to Regenicin in ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... an individual becomes infected with HIV the virus infects ... nervous system [CNS]). Although this causes no immediate problems, ... and encephalitis (acute inflammation of the brain that can ... (SIV) also sometimes develop CNS damage and provide a ...
... A genetic tool used by medical researchers may also be ... viruses from drinking water. , In a series of proof-of-concept ... material could successfully target a matching portion of a gene ... stop working. If this new approach can be perfected, the ...
... Exponent, Inc.,(Nasdaq: EXPO ) announced today ... an additional $35,000,000 for the repurchase of Exponent,s ... transactions in compliance,with Securities and Exchange Commissions Rule ... the future cash flow of the,Company, as well ...
Cached Biology Technology:Possible new approach to purifying drinking water 2Possible new approach to purifying drinking water 3Exponent Adds $35 Million to Stock Repurchase Program 2
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... ,A new EU project, METSY, develops and applies ... metabolism is connected to psychotic disorders and metabolic ... The overall objective is to identify, prioritize and ... diagnostic potential for prediction and monitoring psychotic disorders ...
... by ChipCare Corporation, has secured one of the ... Phase II financing has closed, with an investment ... commercialization over the next three years. The ... among Canadian social angel investors, including Maple Leaf ...
... of Geneva (UNIGE),s Faculty of Medicine in the context of ... the genetic causes of differences between people. The study, published ... the largest-ever dataset linking human genomes to gene activity at ... genome makes them more or less susceptible to disease is ...
Cached Biology News:ChipCare's handheld analyzer attracts one of Canada's largest-ever healthcare angel investments 2Functional genetic variation in humans: Comprehensive map published 2
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
... Mouse monoclonal antibody raised against ... Immunogen: HD ... a.a) partial recombinant protein with ... Accession Number: NM_002111 ...
Biology Products: